Nakamoto Inc. (NAKA) has justified retaining a Chief Medical Officer (CMO) despite financial challenges, including a 99% share price collapse and $200 million in debt. CEO David Bailey explained that the CMO position is a legacy from Nakamoto's reverse merger with KindlyMD, a healthcare provider, which is necessary to maintain Nasdaq listing requirements. The healthcare arm remains a key revenue source, preventing the company from being classified as a shell entity. The role has drawn criticism amid broader concerns over Nakamoto's financial health. The company's Q1 2026 report revealed a $238 million net loss, with operating revenue at $2.3 million and insider compensation totaling $7.3 million. A recent acquisition led to a 58% dilution of public shareholders, prompting a 1-for-40 reverse stock split to meet Nasdaq's minimum bid requirements. The split increased NAKA's share price from $0.16 to approximately $6, reducing outstanding shares to 17.4 million. Investors remain focused on upcoming financial disclosures and the impact of the BTC Inc. acquisition.